Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
Holding BHVN?
Track your performance easily
BHVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.45 - $62.21
Previous Close$39
Volume1.10M
Average Volume (3M)922.49K
Market Cap
$3.69B
Enterprise Value$3.28B
Total Cash (Recent Filing)$436.95M
Total Debt (Recent Filing)$26.19M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Nov 06, 2024EPS Estimate
-$1.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.15
Shares Outstanding94,542,253
10 Day Avg. Volume824,355
30 Day Avg. Volume922,486
Standard Deviation0.38
R-Squared0.19
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)12.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.69
Forecast
1Y Price Target
$57.67Price Target Upside46.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Biohaven Ltd. News
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressFive BHV-7000 (Kv7 activator) Ph2/3 trials are underway in epilepsy, major depressive disorder (MDD) and bipolar disorder.
Drug DevelopmentBHVN is on track to report taldefgrobep alfa (myostatin inhibitor) Ph3 data in SMA and initiate a Ph2 obesity trial.
Pipeline PotentialThe current market cap of approximately $3.6 billion is baking in total pipeline contribution of around $1 billion, but the pipeline could approach $3 to 4 billion over time.
Bears Say
Clinical TrialsThere is some risk in near-term read-out, such as the SMA trial potentially missing its targets, and the company has high cash burn.
Data DelaysThe stock has pulled back approximately 36% primarily due to delays and underwhelming initial IgG degrader data.
Investor SentimentInvestor concerns over plateauing effect are driving a selloff.
---
Ownership Overview
14.66% Insiders
24.31% Mutual Funds
47.78% Other Institutional Investors
13.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $16.45 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Currently, no data Available
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Aug 08, 2024. The company reported -$3.64 earnings per share for the quarter, missing the consensus estimate of -$1.781 by -$1.859.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -$1.74.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 94,542,250 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$3.64 in its last earnings report, missing expectations of -$1.781. Following the earnings report the stock price went up 6.253%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Among the largest hedge funds holding Biohaven Ltd.’s share is Farallon Capital Management, L.L.C.. It holds Biohaven Ltd.’s shares valued at 78M.
---
Biohaven Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.67 (46.37% Upside)
$57.67 (46.37% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
104.18%
12-Months-Change
Fundamentals
Return on Equity
-193.67%
Trailing 12-Months
Asset Growth
14.98%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Month Forecast
Average Price Target
$57.67
▲(46.37% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+20.30%
assigned a buy rating last month
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +20.30% per trade.
---